(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 28.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Tg Therapeutics's revenue in 2026 is $799,536,000.On average, 9 Wall Street analysts forecast TGTX's revenue for 2026 to be $149,917,361,199, with the lowest TGTX revenue forecast at $142,507,288,343, and the highest TGTX revenue forecast at $157,967,262,696. On average, 9 Wall Street analysts forecast TGTX's revenue for 2027 to be $203,275,702,384, with the lowest TGTX revenue forecast at $182,764,449,282, and the highest TGTX revenue forecast at $227,766,750,864.
In 2028, TGTX is forecast to generate $256,849,870,934 in revenue, with the lowest revenue forecast at $221,337,850,638 and the highest revenue forecast at $302,311,379,675.